Novartis (VTX:NOVN) Given a CHF 110 Price Target by Goldman Sachs Group Analysts

Share on StockTwits

Goldman Sachs Group set a CHF 110 price objective on Novartis (VTX:NOVN) in a report released on Wednesday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

Several other research firms have also recently commented on NOVN. Deutsche Bank set a CHF 92 target price on shares of Novartis and gave the company a neutral rating in a research note on Monday, April 6th. Jefferies Financial Group set a CHF 100 target price on shares of Novartis and gave the company a buy rating in a research note on Tuesday, April 28th. Morgan Stanley set a CHF 93 target price on shares of Novartis and gave the company a neutral rating in a research note on Wednesday, March 11th. UBS Group set a CHF 88 target price on shares of Novartis and gave the company a neutral rating in a research note on Thursday, May 21st. Finally, Oddo Bhf set a CHF 89 target price on shares of Novartis and gave the company a buy rating in a research note on Tuesday, March 31st. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. Novartis currently has an average rating of Hold and an average price target of CHF 92.77.

Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Read More: How to Invest in Marijuana Stocks

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply